| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
CH:ALC
Alcon
|
Sep 22, 2026 | HOLD |
Buy
+32.9% avg upside
36 analysts
|
— | -1.3% | · |
|
CLPT
ClearPoint Neuro
|
Sep 15, 2026 | BUY |
Strong Buy
+48.3% avg upside
7 analysts
|
— | +12.8% | · |
|
TMDX
TransMedics Group
|
Sep 11, 2026 | HOLD |
Strong Buy
+13.5% avg upside
15 analysts
|
$65.00
23.80% Downside
|
+3.8% | · |
|
GKOS
Glaukos
|
Sep 04, 2026 | BUY |
Strong Buy
+12.3% avg upside
21 analysts
|
$190.00
23.04% Upside
|
-9.0% | · |
|
BLCO
Bausch + Lomb Corporation
|
Aug 25, 2026 | HOLD |
Buy
+19.7% avg upside
20 analysts
|
$16.00
5.19% Downside
|
-1.9% | · |
|
STAA
Staar Surgical
|
Aug 17, 2026 | HOLD |
Hold
+65.7% avg upside
16 analysts
|
$28.00
36.51% Upside
|
-17.8% | · |
|
GMED
Globus Medical
|
Aug 11, 2026 | HOLD |
Strong Buy
+24.5% avg upside
24 analysts
|
$85.00
14.16% Upside
|
-13.1% | · |
|
RXST
RxSight
|
Aug 10, 2026 | HOLD |
Hold
+94.3% avg upside
13 analysts
|
$7.00
50.22% Upside
|
-29.1% | · |
|
SGHT
Sight Sciences
|
Aug 06, 2026 | BUY |
Strong Buy
+6.2% avg upside
13 analysts
|
$8.00
10.44% Downside
|
+25.9% | · |
|
OFIX
Orthofix Medical
|
Aug 05, 2026 | BUY |
Buy
+198.6% avg upside
15 analysts
|
$13.00
37.77% Upside
|
-9.4% | · |
|
ATEC
Alphatec Holdings
|
Jul 08, 2026 | BUY |
Strong Buy
+64.1% avg upside
23 analysts
|
$13.00
28.50% Upside
|
+9.9% | · |
|
SGP
SpyGlass Pharma
|
May 15, 2026 | BUY |
Strong Buy
+62.9% avg upside
6 analysts
|
$42.00
55.20% Upside
|
+16.6% | · |
|
IRIX
Iridex
|
May 15, 2024 | HOLD |
Strong Buy
+633.3% avg upside
3 analysts
|
$2.00
219.91% Upside
|
-62.3% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.